A 52-year-old woman with acute coronary syndrome is admitted to the coronary care unit. She receives aspirin, clopidogrel, and is started on a β-blocker (metoprolol) for rate control and cardioprotection. However, 6 hours after admission, she develops acute bronchospasm with wheezing, dyspnea (RR 28/min), and oxygen saturation drop to 88% on room air. She has a history of mild asthma (not on regular medications). The β-blocker is immediately discontinued. Which β-adrenergic receptor subtype blockade is responsible for the bronchospasm, and why would a β1-selective agent have been safer in this patient?

Explanation

## β-Blocker-Induced Bronchospasm: Receptor Selectivity and Clinical Safety ### β-Adrenergic Receptor Distribution and Function **Key Point:** β2-adrenergic receptors are the predominant receptors in bronchial and bronchiolar smooth muscle. Activation of β2 receptors causes bronchodilation via increased cAMP and smooth muscle relaxation. Blockade of β2 receptors removes this protective bronchodilatory tone, leading to unopposed bronchoconstriction. ### β-Blocker Selectivity and Airway Effects | Parameter | Non-Selective β-Blockers (e.g., Propranolol, Metoprolol at high doses) | β1-Selective Agents (e.g., Metoprolol at low doses, Atenolol, Bisoprolol) | |-----------|---------|----------| | **β1 Blockade** | Yes (cardiac) | Yes (cardiac) | | **β2 Blockade** | Yes (bronchi, blood vessels) | Minimal to none (dose-dependent) | | **Bronchospasm Risk** | High, especially in asthmatics | Low; β2 receptors remain functional | | **Vasodilation** | Impaired (β2 blockade in vessels) | Preserved | | **Cardioprotection** | Excellent | Excellent | | **Asthma/COPD Safety** | Contraindicated | Relatively safe (with caution) | **High-Yield:** The critical distinction is **β1-selectivity vs. non-selectivity**. At therapeutic doses, β1-selective agents (selectivity ratio ~75:1 for atenolol, ~40:1 for metoprolol) preferentially block cardiac β1 receptors while sparing β2 receptors in airways. Non-selective agents block both β1 and β2 equally, removing the protective β2-mediated bronchodilation. ### Mechanism of Bronchospasm in This Patient **Clinical Pearl:** This patient developed acute bronchospasm because: 1. Metoprolol (non-selective at higher doses) blocked β2 receptors in bronchial smooth muscle 2. Loss of β2-mediated bronchodilation → unopposed parasympathetic (M3) and other constrictive influences 3. Her underlying mild asthma increased baseline airway reactivity and susceptibility to β2 blockade 4. The acute coronary syndrome context (stress, catecholamine surge) made the loss of β2 protection especially dangerous ### Why β1-Selective Agents Are Safer **Mnemonic: SAFE** — Selective for β1, Airway β2 spared, Fewer bronchospasm episodes, Excellent cardiac protection maintained. β1-selective agents (atenolol, bisoprolol, carvedilol) at therapeutic doses: - Block cardiac β1 receptors → reduced heart rate, contractility, AV conduction (cardioprotection in ACS) - Spare airway β2 receptors → preserved bronchodilation, minimal bronchospasm risk - Maintain β2-mediated vasodilation in peripheral vessels ### Clinical Management 1. **Immediate:** Discontinue non-selective β-blocker (already done) 2. **Substitute:** Switch to β1-selective agent (e.g., atenolol 25 mg daily, bisoprolol 1.25 mg daily, or low-dose metoprolol 25 mg daily) 3. **Airway Management:** Oxygen, bronchodilators (β2-agonist inhaler), consider IV magnesium or corticosteroids if severe 4. **Future:** Document β-blocker intolerance; always use β1-selective agents in patients with asthma/COPD [cite:Harrison 21e Ch 246; KD Tripathi 8e Ch 10]